| 000 | 01380 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250515133943.0 | ||
| 264 | 0 | _c20080924 | |
| 008 | 200809s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMe0806806 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKent, David M | |
| 245 | 0 | 0 |
_aStroke prevention--insights from incoherence. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cSep 2008 |
||
| 300 |
_a1287-9 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAspirin _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzimidazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzoates _xtherapeutic use |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 |
_aDipyridamole _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 |
_aStroke _xdrug therapy |
| 650 | 0 | 4 | _aTelmisartan |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 700 | 1 | _aThaler, David E | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 359 _gno. 12 _gp. 1287-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMe0806806 _zAvailable from publisher's website |
| 999 |
_c18224431 _d18224431 |
||